Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
The conversation discusses a user's three-month progress using topical finasteride once a day, 6% minoxidil at night, and weekly dermastamping at 1.25mm for hair loss. Commenters note the impressive results and discuss application methods and safety precautions for family members.
The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.
The user reports significant hair regrowth after 90 days using oral finasteride, minoxidil, and biotin. Another user comments on the impressive progress and predicts even thicker hair in a year.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
A 3-month update on a microneedling-only project to treat hair loss, which has not had significant results in terms of thicker hair but may have seen some acceleration in hair growth and an increase in vellus hairs. The user plans to continue the journey for 6 months before making any changes, such as adding minoxidil or finasteride.
A 24-year-old man saw hair loss improvement after 5 months using 1 mg finasteride daily, 5% minoxidil nightly, weekly microneedling with a Dr. Pen A6 at 1.5mm, daily biotin (at least 10,000 mcg), and using a shampoo for thinning hair every other day. He experienced no side effects and confirmed his health with bloodwork.
The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.
A user shared their 3-month hair growth progress using 1mg oral finasteride, 5% topical minoxidil, and microneedling with a 1.5 mm dermaroller twice weekly. The user received positive feedback and expressed a desire for thicker hair in the future.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
A user who has been using the "Big 3" hair loss treatments (ketoconazole, minoxidil and finasteride) for 2-3 months and is hoping to see positive results. The other user commented that they look like a hyper responder and asked if they were using oral or topical fin/min.
The user is using a hair loss treatment involving dutasteride, minoxidil, finasteride, microneedling, and supplements like multivitamins, D3 K2, and Omega 3 fish oil. They are considering adding tretinoin and are open to suggestions while managing gut issues.
MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.
Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.
The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.
The user experienced significant hair regrowth and thickening using Minoxidil, Finasteride, and Regenepure DR. They reported no major side effects except for an itchy scalp.
Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.
Minoxidil combined with tretinoin may improve hair regrowth due to their synergistic effects. Using a gel with 0.025% tretinoin and antibiotics might still be beneficial.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.
The post and conversation are about a user's 4-month hair regrowth progress using 3mg minoxidil, 2.5mg biotin, 1.1mg finasteride daily, and occasional dermarolling. The user reports significant improvement without using topical treatments.